Safety and Efficacy Study of NFC-1 in Subjects Aged 12-17 Years With 22q11.2DS & Associated Neuropsychiatric Conditions
Status:
Completed
Trial end date:
2017-04-20
Target enrollment:
Participant gender:
Summary
This is a 5-week, multi-center, open-label, dose optimization trial in subjects aged 12-17
years with 22q11DS who have a diagnosis of anxiety disorder, and/or ADHD, and/or ASD.
Approximately 12 subjects will be initiated, dose optimized, and maintained on NFC-1 over a
period of 5 weeks.
Phase:
Phase 1
Details
Lead Sponsor:
Aevi Genomic Medicine Aevi Genomic Medicine, LLC, a Cerecor company